GSE129944
Drug combination of 17-AAG and Belinostat on MDA-MB-231 breast cancer cells
Breast cancer is the most common cancer that threatens women's health. While the strategy of drug combination can help to reduce adverse effects and to overcome the resistance of clinical treatment of single drug. In this work, we report the synergetic effect between a HSP90 inhibitor 17-AAG and a HDAC inhibitor Belinostat, on the triple-negative breast cancer MDA-MB-231 cells. The RNA-Seq data analysis showed that the most over-represented KEGG pathways in the combination group came from migration or invasion related genes, which were not observed in the differentially expressed genes after the treatment of 17-AAG or Belinostat alone. Overall design: The RNA-Seq data was collected for MDA-MB-231 cells after the treatment of 17-AAG, Belinostat, and the Combination of 17-AAG with Belinostat